



# 2018 Oral ondansetron (oral generic Zofran®) Prior Authorization Request

oral ondansetron is available in tablets, oral disintegrating tablets (ODT) and oral solution

Page 1 of 2

(You must complete both pages.)

Fax completed form to: 1-800-408-2386

For urgent requests, please call: 1-800-414-2386

Patient information		Prescriber information	
Patient name		Today's date	Physician specialty
Patient insurance ID number		Physician name	NPI/DEA number
Patient address, city, state, ZIP		Physician address, city, state, ZIP	
Patient home telephone number		MD office telephone number	
Gender <input type="checkbox"/> Male <input type="checkbox"/> Female	Patient date of birth	MD office fax number	
Diagnosis and medical information			
Medication requested			Frequency
<input type="checkbox"/> ondansetron hcl: <input type="checkbox"/> 8 mg tablet <input type="checkbox"/> 4 mg tablet <input type="checkbox"/> 24 mg tablet <input type="checkbox"/> 4 mg/5ml oral solution			
<input type="checkbox"/> ondansetron orally disintegrating tablets (ODT): <input type="checkbox"/> 8 mg tablet <input type="checkbox"/> 4 mg tablet			
New prescription OR date therapy initiated		Quantity	Day supply
			Expected length of therapy
Diagnosis ( <i>Please check all boxes that apply and include all office notes supporting diagnosis.</i> )			
<input type="checkbox"/> Chemotherapy-induced nausea and vomiting, highly emetogenic chemotherapy, prophylaxis			
<input type="checkbox"/> Chemotherapy-induced nausea and vomiting, moderately emetogenic chemotherapy, prophylaxis			
<input type="checkbox"/> Postoperative nausea and vomiting, prophylaxis			
<input type="checkbox"/> Radiation-induced nausea and vomiting, prophylaxis			
Other diagnosis/(ICD 10): _____			
Please check all boxes that apply:			
1. <input type="checkbox"/> Yes <input type="checkbox"/> No Is oral ondansetron being used for chemotherapy induced nausea and vomiting? If YES, complete the section below.			
a. Cancer diagnosis: _____			
b. Cancer chemotherapy regimen: _____			
c. Frequency of cancer chemotherapy: _____ Number of cycles: _____			
d. Cancer chemotherapy route of administration: <input type="checkbox"/> Intravenous (IV) <input type="checkbox"/> Oral (PO) <input type="checkbox"/> Other: _____			
e. Where is the chemotherapy being administered? <input type="checkbox"/> Home <input type="checkbox"/> Hospital <input type="checkbox"/> Outpatient infusion center <input type="checkbox"/> Other: _____			
<input type="checkbox"/> Yes <input type="checkbox"/> No Is the requested drug being used as a full therapeutic replacement* for an intravenous antiemetic (IV) drug that would otherwise have been administered at the time of the chemotherapy treatment? <i>*Full therapeutic replacement for an IV antiemetic is when the patient <b>DID NOT</b> receive any doses of IV antiemetic at the time of chemotherapy administration.</i>			
<input type="checkbox"/> Yes <input type="checkbox"/> No Will the requested drug be given within two hours of chemotherapy administration <b>AND</b> continued for a period <b>NOT EXCEEDING</b> 48 hours from that time?			
<input type="checkbox"/> Yes <input type="checkbox"/> No Will the requested drug be given <b>AFTER</b> 48 hours of chemotherapy administration for ongoing nausea/vomiting?			

(continued on page 2)

**Fax Confidentiality Notice:** The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. **If you received this transmission in error, please notify us immediately by telephone at 1-800-414-2386.**

**Please check all boxes that apply (continued):**

2.  Yes  No **The quantity limit for ondansetron oral solution 4mg/5ml is 900 ml per 30 days. Does the patient require a higher dosage (quantity limit exception)?**

▶ If **YES**, indicate quantity requested: \_\_\_\_\_ per 30 days **OR** quantity \_\_\_\_\_ per day

- The number of doses available under the dose restriction for the prescription drug has been ineffective in the treatment of the enrollee's disease or medical condition.
- The number of doses available under the dose restriction for the prescription drug, based on both sound clinical evidence and medical and scientific evidence, the known relevant physical or mental characteristics of the enrollee and known characteristics of the drug regimen, is likely to be ineffective or adversely affect the drug's effectiveness or patient compliance.

3.  **Please list all medications the patient has tried specific to the diagnosis and specify below.**

CURRENT/PAST MEDICATIONS USED	DATES OF TREATMENT	THERAPEUTIC OUTCOME

4.  **Other supporting information**

\*NOTE: All exception requests require prescriber supporting statements. Additionally, requests that are subject to prior authorization (or any other utilization management requirement), may require supporting information. Please attach supporting information, as necessary, for your request.

---



---



---



---

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that documentation supporting this information is available for review if requested by the health plan sponsor, or, if applicable, a state or federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733. By signing this form, I represent that I have obtained patient consent as required under applicable state and federal law, including but not limited to the Health Information Portability and Accountability Act (HIPAA) and state re-disclosure laws related to HIV/AIDS.

<b>Prescriber signature</b>	<b>Date</b>
-----------------------------	-------------